Filing Flows › Whitehawk Therapeutics (WHWK) › Q4 2024 › vs Q4 2023
Whitehawk Therapeutics (WHWK) Q4 2024 vs Q4 2023 (year over year)
Whitehawk Therapeutics's revenue rose $913K (+14%) from $6.3M in Q4 2023 to $7.2M in Q4 2024.
Whitehawk Therapeutics, Q4 2024: revenue $7.2M (+14% year over year), operating margin -261.8%, net loss $18.3M, operating cash flow −$15.1M. The chart draws each line against Q4 2023, the increases inside each band.
Every line
| Line | Q4 2024 | Q4 2023 | Change | % |
|---|---|---|---|---|
| Revenue | $7.2M | $6.3M | $913K | +14% |
| Other income, net | $676K | $1.4M | −$769K | -53% |
| Net loss | $18.3M | $16.3M | $2.0M | +12% |
| Costs & expenses | $26.2M | $24.0M | $2.1M | +9% |
| Operating costs | $26.2M | $24.0M | $2.1M | +9% |
| Cost of revenue | $790K | $927K | −$137K | -15% |
| Research & development | $14.3M | $12.8M | $1.6M | +12% |
| SG&A | $11.1M | $10.3M | $706K | +7% |
| Operating cash sources | $18.3M | $16.3M | $2.0M | +12% |
| Depreciation | $54K | $44K | $10K | +23% |
| Share-based compensation | $1.9M | $3.1M | −$1.3M | -40% |
| Working capital & other | $1.3M | $3.5M | −$2.2M | -62% |
| Cash used in operations | $15.1M | $9.6M | $5.4M | +56% |
| Net loss absorbed | $18.3M | $16.3M | $2.0M | +12% |
Questions
How much did Whitehawk Therapeutics's revenue grow year over year in Q4 2024?
Whitehawk Therapeutics's revenue rose $913K (+14%) from $6.3M in Q4 2023 to $7.2M in Q4 2024.